Filtered By:
Specialty: Drugs & Pharmacology
Drug: Warfarin

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 300 results found since Jan 2013.

Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan.
CONCLUSION: Although most participants in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial used for the efficacy data of apixaban in the model were non-Japanese patients, the impact of the limitations on our results was considered small, and our results were deemed robust because of the additional effect in Japanese patients compared with that in the global population according to the subanalysis of Japanese patients in the trial. Therefore, based on an adaptation of a published Markov model, apixaban is a cost-effective alternative to warfarin in Japan for strok...
Source: Clinical Therapeutics - November 19, 2015 Category: Drugs & Pharmacology Authors: Kamae I, Hashimoto Y, Koretsune Y, Tanahashi N, Murata T, Phatak H, Liu LZ, Tang AC, Feng Wang P, Okumura K Tags: Clin Ther Source Type: research

Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.
CONCLUSION: Our DA to allow patients to make an informed decision with their physician regarding dabigatran versus warfarin in AF, proved understandable, comprehensive and helpful. PMID: 24163147 [PubMed - indexed for MEDLINE]
Source: Journal of Population Therapeutics and Clinical Pharmacology - October 26, 2015 Category: Drugs & Pharmacology Tags: J Popul Ther Clin Pharmacol Source Type: research

Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.
In this study we analyzed changes in prescription volumes for OAC drugs since the introduction of the NOACs in Canada overall, by province and by physician specialty. METHODS: Canadian prescription volumes for warfarin, dabigatran, rivaroxaban, and apixaban from January 2008 to June 2014 were obtained from the Canadian Compuscript Audit of IMS Health Canada Inc and were analyzed by physician specialty at the national and provincial levels. Total prescriptions by indication were calculated based on data from the Canadian Disease and Therapeutic Index for all OAC indications and for each commonly prescribed dose of dabi...
Source: Clinical Therapeutics - October 16, 2015 Category: Drugs & Pharmacology Authors: Weitz JI, Semchuk W, Turpie AG, Fisher WD, Kong C, Ciaccia A, Cairns JA Tags: Clin Ther Source Type: research

Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities
Abstract The presence of atrial fibrillation (AF), the most common sustained cardiac arrhythmia, significantly increases the risk for stroke. Current guidelines recommend that the vitamin K antagonist warfarin or direct oral anticoagulants (DOACs), such as the approved direct thrombin inhibitor dabigatran and the approved direct factor Xa inhibitors apixaban, rivaroxaban, and edoxaban, should be used for thromboprophylaxis in patients with nonvalvular AF at risk for stroke or systemic embolic events (SEE). Warfarin, the mainstay of stroke prevention in AF, increases the risk of major bleeding. Furthermore, warfari...
Source: Drugs - September 14, 2015 Category: Drugs & Pharmacology Source Type: research

Warfarin and Aspirin Use for Stroke Prevention Among Patients With Atrial Fibrillation: The US National Health and Wellness Survey
This study examined VKA and ASA use and their clinical correlates, including CHADS2 stroke risk scores, among adult patients with AF in the general population. Participants included 1290 (1.72%) adults reporting diagnosis with AF (mean age, 64.9 years; 65% men) from the 2009 US National Health and Wellness Survey, an online, self-administered, nationwide, stratified random sample survey of 75,000 adults. Antithrombotic use patterns, including VKA, ASA, VKA+ASA, and non-VKA/ASA, and their correlates were examined using logistic regressions. Respondents with AF were treated with VKA (26.6%), ASA (34.5%), VKA+ASA (15.4%), or ...
Source: American Journal of Therapeutics - July 1, 2015 Category: Drugs & Pharmacology Tags: Original Articles Source Type: research

Matching on the disease risk score in comparative effectiveness research of new treatments
ConclusionsWhen PS distributions are separated, DRS matching can improve the precision of effect estimates and allow researchers to evaluate the treatment effect in a larger proportion of the treated population. However, accurately modeling the DRS can be challenging compared with the PS. Copyright © 2015 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - June 25, 2015 Category: Drugs & Pharmacology Authors: Richard Wyss, Alan R. Ellis, M. Alan Brookhart, Michele Jonsson Funk, Cynthia J. Girman, Ross J. Simpson, Til Stürmer Tags: Original Report Source Type: research

INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation
Conclusion The intensity of anticoagulation therapy for Korean patients with NVAF is optimal when INR is between 1.7 and 2.2.
Source: International Journal of Clinical Pharmacy - June 12, 2015 Category: Drugs & Pharmacology Source Type: research

Antithrombotic options for atrial fibrillation in 2012.
Authors: Rude J, Quevedo K, Rodriguez de Armas L, Mukherjee D Abstract Atrial fibrillation (AF) is a common arrhythmia in clinical practice. An important component of the management of patients with AF involves prevention of thromboembolism and stroke. Coumarins, such as warfarin had been the only available oral antithrombotic agent for prevention of thromboembolism for many decades. Following intestinal absorption, coumarins inhibit multiple steps of the clotting cascade that leads to inhibition of coagulation factors II, VII, IX and X. In addition to delayed and variable inhibition of coagulation, coumarin therap...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
Authors: Turagam MK, Velagapudi P, Bongu NR, Kocheril AG Abstract Warfarin has remained the mainstay of stroke prevention in atrial fibrillation for the past 60 years. Recently, two new groups of novel oral anticoagulants- direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) have shown promising results in well conducted clinical trials in terms of efficacy, safety and convenience of usage. However, in real world practice these novel agents come with their share of side effects and drawbacks which the prescribing physician must be aware about. In this review we discuss ...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Atrial fibrillation - new frontiers in anticoagulation.
Authors: Thomas R, Page PL, Mitchell AR Abstract Stroke is the most feared complication of atrial fibrillation but for over fifty years there has been no simple, effective preventative alternative to warfarin. The development of new risk algorithms such as CHADSVASC has resulted in more patients being recommended anticoagulation therapy. Fixed dose oral anticoagulation is a landmark in drug development for atrial fibrillation. The differences between the drugs are discussed and the trial data examined. As we enter this new frontier of therapy, there is no doubt that these drugs will transform the delivery of antico...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital
The objective of this study was to evaluate the appropriateness of rivaroxaban dosing, indication and safety in a community hospital and to identify areas for improvement in its use. MethodsThis single‐centre, retrospective review evaluated patients who received at least one dose of rivaroxaban between November 2011 and July 2013. The primary outcome included appropriateness of the first day of therapy based on indication and renal function per FDA‐approved dosing recommendations for the prevention of stroke and systemic embolism in non‐valvular atrial fibrillation (NVAF) and for the treatment or prevention of venous...
Source: Journal of Clinical Pharmacy and Therapeutics - May 26, 2015 Category: Drugs & Pharmacology Authors: K. B. Tellor, S. Patel, A. L. Armbruster, M. W. Daly Tags: Original Article Source Type: research

Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice
The objective of this review is to provide the clinician with an update on the use of NOACs for NVAF, focusing on older adults and patients with renal impairment in light of recently published atrial fibrillation guidelines. Available data on using NOACs in coronary artery stenting, cardioversion, and ablation are also reviewed.
Source: Drugs - May 22, 2015 Category: Drugs & Pharmacology Source Type: research

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation
Tushar Acharya, Prakash Deedwania Division of Cardiology, Department of Internal Medicine, University of California, San Francisco, Fresno, CA, USA Abstract: Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke. As a result, atrial fibrillation patients are risk-stratified using the CHADS2 or CHA2DS2-VASc scoring systems. Those at intermediate-to-high risk have traditionally been treated with therapeutic anticoagulation with warfarin for stroke prevention. Although effective, warfarin use is fraught with mult...
Source: Core Evidence - April 27, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Edoxaban, a Novel Oral Factor Xa Inhibitor.
CONCLUSIONS: Edoxaban is a safe and effective anticoagulant to reduce the risk of stroke in patients with NVAF and for the treatment of VTE. PMID: 25855704 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - April 8, 2015 Category: Drugs & Pharmacology Authors: Minor C, Tellor KB, Armbruster AL Tags: Ann Pharmacother Source Type: research

Comparison of warfarin time in the therapeutic range at a pharmacist-run anticoagulation clinic and the RE-LY trial.
CONCLUSION: TTR values among PAC-managed patients with nonvalvular atrial fibrillation were comparable to those reported in the RE-LY trial. PMID: 25788509 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - March 20, 2015 Category: Drugs & Pharmacology Authors: Biszewski M, Nitzki-George D, Zhou Y Tags: Am J Health Syst Pharm Source Type: research